The role of B7-2 (CD86) in tumour immunity

G. Yang, K. E. Hellstrom, L. Chen

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Tumour cells engineered to express co-stimulatory molecules on their surface provide researchers with powerful new tools to manipulate antitumour responses. It has been demonstrated that B7-1+ and B7-2+ tumour cells can elicit effective responses against their wild-type counterparts. This response is primarily mediated by CD8+ cytolytic T-lymphocytes. The co- stimulatory ability of B7-2+ tumour cells is comparable to that of B7-1+ tumour cells, though with some exceptions. However, on host antigen- presenting cells (APC), B7-2 plays a dominant role in inducing T-cell- mediated immune responses. Up-regulation of B7-2 on host APC may, therefore, present an effective means of generating potent antitumour immunity.

Original languageEnglish (US)
Pages (from-to)677-684
Number of pages8
JournalExpert Opinion on Investigational Drugs
Issue number6
StatePublished - 1997
Externally publishedYes


  • B7 co-stimulation
  • T-cell activation
  • Tumour immunotherapy 677-684

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'The role of B7-2 (CD86) in tumour immunity'. Together they form a unique fingerprint.

Cite this